Skip to main content

Alkermes Value Stock - Dividend - Research Selection

Alkermes

ISIN: IE00B56GVS15 , WKN: A1JKVH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company\'s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month

2023-09-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Alkermes Pathways Research Awards Is Now Accepting Applications!

2023-09-19
The Alkermes Pathways Research Awards are open for applications! This program is open to all early-career investigators studying bipolar disorder or schizophrenia.

Alkermes Commemorates World Suicide Prevention Day

2023-09-18
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Alkermes (ALKS) Stock Moves -0.84%: What You Should Know

2023-09-15
Alkermes (ALKS) closed the most recent trading day at $29.60, moving -0.84% from the previous trading session.

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Alnylam Pharma (ALNY)

2023-09-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

For Potential Alkermes Buyers, There's a Key Price Level to Watch

2023-09-13
Biopharmaceutical firm Alkermes plc has been trading sideways since February. The On-Balance-Volume (OBV) line shows some weakness from June into late August but it is now improving. The Moving Average Convergence Divergence (MACD) oscillator has been improving and shows a bullish divergence in August when the shares made a lower low.

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

2023-09-11
Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville. This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.

Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

2023-09-08
Alkermes (ALKS) closed the most recent trading day at $28.85, moving -1.16% from the previous trading session.

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program

2023-09-07
Alkermes plc (Nasdaq:ALKS) announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 15, 2023. Now in its sixth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience.

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

2023-09-07
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.